7827 — HanchorBio Income Statement
0.000.00%
Last trade - 00:00- TWD22.34bn
- TWD21.73bn
- TWD312.22m
Annual income statement for HanchorBio, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 3.36 | 0 | 0 | 312 |
| Cost of Revenue | ||||
| Gross Profit | 2.05 | 0 | 0 | 312 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Total Operating Expenses | 516 | 538 | 952 | 680 |
| Operating Profit | -512 | -538 | -952 | -368 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -446 | -591 | -1,354 | -369 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -446 | -591 | -1,354 | -392 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -446 | -591 | -1,354 | -277 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -446 | -591 | -1,354 | -277 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -3.68 | -4.87 | -11.2 | -2.26 |
| Dividends per Share |